Updated

Updated · The Jerusalem Post · Jun 13

Cellular Intelligence Hosts 28-Expert AI Symposium After Novo Nordisk Parkinson’s Therapy Deal

Updated

Updated · The Jerusalem Post · Jun 13

Cellular Intelligence Hosts 28-Expert AI Symposium After Novo Nordisk Parkinson’s Therapy Deal

Q: With a Parkinson's cure in sight, what is the next disease Cellular Intelligence's powerful AI platform will target for elimination?

There is no confirmed “next disease” yet. Cellular Intelligence is currently centered on Parkinson’s disease through the STEM-PD program it acquired from Novo Nordisk, and the available reporting does not name a single follow-on target for elimination. The company says its AI platform could be applied more broadly, but it has not publicly committed to one disease as the next program after Parkinson’s. What has been identified are several likely areas of expansion. In remarks tied to the symposium and related coverage, CEO Dr. Micha Breakstone pointed to Type 1 diabetes, epilepsy, and macular degeneration as diseases the platform could help address. Cancer also appears to be a particularly strong candidate: Breakstone reportedly described it as “really interesting” and said the company is already thinking about how to learn from cancer’s evolution and behavior. That said, the evidence supports a cautious reading. Parkinson’s is not yet a cure “in sight” in the strict clinical sense; STEM-PD is still an investigational therapy in Phase 1/2 testing. And while Cellular Intelligence’s broader ambition is to build a foundation model that can design and manufacture many cell therapies, the company has not publicly announced which disease will come next. So the most accurate answer is that no next disease has been officially named, though cancer, Type 1 diabetes, epilepsy, and macular degeneration are the clearest candidates mentioned so far.

3 articles · Updated · The Jerusalem Post · Jun 13

One day after securing global rights to Novo Nordisk’s clinical-stage Parkinson’s cell therapy, Cellular Intelligence convened 28 experts in Copenhagen to push AI-driven regenerative medicine.
The Boston-based company says its platform combines high-throughput cell data with a foundation model trained on millions of cellular perturbation conditions to speed development, cut manufacturing costs and improve consistency at scale.
Its STEM-PD program aims to replace lost dopamine-producing neurons rather than just manage Parkinson’s symptoms, while founder Micha Breakstone said the same approach could extend to Type 1 diabetes, epilepsy and macular degeneration.
Copenhagen’s biotech ecosystem is central to that plan: Breakstone called Denmark a “perfect home,” and BioInnovation Institute CEO Jens Nielsen said AI can shorten preparation, analysis, development time and cost.
The deal and symposium underscore a broader bet that AI-native biology platforms can turn cell therapy from slow trial-and-error work into predictive engineering with commercial potential.

Sources

The Jerusalem Post1d ago

Cellular Intelligence Hosts AI & Biology Symposium Post-Novo Nordisk Parkinson's Cell Therapy Acquisition

linkedin1d ago

cellularintelligence #stempd #parkinsonsdisease #stemcelltherapy #aimedicine | Rick Spair

letsdatascience.com1d ago

Cellular Intelligence Acquires Global Rights to STEM-PD | Let's Data Science

4 Sources

With a Parkinson's cure in sight, what is the next disease Cellular Intelligence's powerful AI platform will target for elimination?

If AI can now design human cells to cure disease, what ethical guardrails will prevent it from redesigning humanity itself?

Is 'decoding' cell fate with AI truly the next AlphaFold moment, or is biology simply too complex to be engineered like code?

Cellular Intelligence Acquires Novo Nordisk’s Parkinson’s Therapy: AI Platform Accelerates Cell Replacement Revolution in Global Biotech Hubs

Overview

In March 2026, Cellular Intelligence acquired Novo Nordisk’s clinical-stage cell therapy program for Parkinson’s disease, positioning itself at the forefront of advanced treatments. By integrating this innovative therapy into its portfolio and applying its AI-native platform, Cellular Intelligence aims to optimize and scale cell therapy programs, marking the start of an AI-driven era in cell replacement therapy. This approach moves beyond traditional biology, using artificial intelligence to design more effective treatments, and signals a new chapter where biology is shaped by intelligent design rather than destiny.

...